Medical Xpress - Cardiology

DECEMBER 13, 2024

However, experts in cardio-oncology from the European Society of Cardiology (ESC) emphasize that heart and cardiovascular health must be included as early as possible in the patient's cancer treatment plan to ensure the best possible outcomes.

Cardio Oncology 98

Cardio Oncology Cancer Outcomes 98

Circulation: Genomic and Precision Medicine

FEBRUARY 24, 2025

Artificial intelligence is poised to transform cardio-oncology by enabling personalized care for patients with cancer, who are at a heightened risk of cardiovascular disease due to both the disease and its treatments. Circulation: Genomic and Precision Medicine, Ahead of Print.

Cardio Oncology 40

Cardio Oncology Cancer Biomarkers Cardiovascular Disease 40

HeartRhythm

AUGUST 31, 2024

The role of wearable technology in detecting AF in cardio-oncology has not been well defined. Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes.

Cardio Oncology 40

Cardio Oncology Technology Atrial Fibrillation Arrhythmia 40

Circulation: Cardiovascular Imaging

JANUARY 8, 2025

As the field of cardio-oncology continues to expand rapidly, guidance on the management of such toxicities and the development of imaging technologies is crucial. These methods have unique considerations and in recent years have made significant progress in their diagnostic capabilities in this patient population.

Cardio Oncology 40

Cardio Oncology Atherosclerosis Cardiomyopathy Cancer 40

Frontiers in Cardiovascular Medicine

FEBRUARY 28, 2024

Cangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial.

Cardio Oncology 69

Cardio Oncology Cancer Patient Care Research 69

DAIC

FEBRUARY 2, 2024

After two full days covering a wide range of issues and experts, the final day will include a joint session with the American College of Cardiology ( ACC ) and the American Society of Clinical Oncology ( ASCO ). Cardio-Oncology Educational Training: What Do I Need to Learn? How to Structure?:

Cardio Oncology 95

Cardio Oncology Cancer Pharmacology RN 95

DAIC

FEBRUARY 28, 2024

The emerging field of cardio-oncology is paving the way for expert, multidisciplinary heart care before, during and after cancer treatment to mitigate adverse effects on cardiovascular health.

Risk Factors 105

Risk Factors Cancer Cardio Oncology Blood Pressure 105

Becker's Hospital Review - Cardiology

OCTOBER 17, 2024

The Heart Failure Society of America has released a scientific statement outlining its insights on the link between heart failure and cancer, the two leading causes of mortality and morbidity in the U.S. The statement was published Oct. 15 in the Journal of Cardiac Failure.

Cardio Oncology 52

Cardio Oncology Heart Failure Cancer 52

European Journal of Heart Failure

MARCH 11, 2025

Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.

Cardio Oncology 40

Cardio Oncology Heart Failure Cancer 40

Circulation

AUGUST 11, 2024

Circulation, Volume 150, Issue 7 , Page 513-515, August 13, 2024.

Cardio Oncology 45

Cardio Oncology Circulation 45

Circulation: Cardiovascular Quality & Outcomes

JANUARY 8, 2025

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print.

Cardio Oncology 40

Cardio Oncology Circulation Outcomes 40

Becker's Hospital Review - Cardiology

NOVEMBER 8, 2024

The annual Global Cardio-Oncology Summit was held in September, bringing together healthcare professionals in the context of cardiovascular disease and cancer.

Cardio Oncology 52

Cardio Oncology Cancer Cardiovascular Disease 52

Frontiers in Cardiovascular Medicine

JANUARY 19, 2024

The baseline risk of CTRCD was graded according to the risk score proposed by the Heart Failure Association (HFA) Cardio-Oncology Working Group and the International Cardio-Oncology Society (ICOS). CTRCD and its severity were defined according to the current European Society of Cardiology (ESC) guidelines.

Cardio Oncology 64

Cardio Oncology Cancer Heart Failure Risk Factors 64

CardiacWire

JUNE 5, 2024

The announcement specifically highlighted Philips’ first-of-their-kind… Segmented Wall Motion app – an automated tool for segmental wall motion scoring and identifying disorders such as coronary artery disease and cardio-oncology issues.

Ultrasound 69

Ultrasound Cardio Oncology Coronary Artery Disease Bicuspid/Mitral 69

Heart BMJ

NOVEMBER 27, 2023

There is need for development of a stronger evidence base to guide clinical practice in cardio-oncology. The establishment of multicentre international registries and national-level healthcare data linkage projects are important steps towards facilitating enrichment of cardio-oncology research programmes.

Cardio Oncology 40

Cardio Oncology Cancer Cardiovascular Disease Risk Factors 40

DAIC

JUNE 12, 2024

The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds.

Ultrasound 105

Ultrasound Cardio Oncology Technology Congenital Heart Disease 105

Open Heart

AUGUST 22, 2022

Further collaborative studies in cardio-oncology with real-world data are warranted to improve the rate of baseline cardiovascular risk assessment in patients with cancer scheduled for cardiotoxic cancer treatment. Baseline cardiac evaluation in the combined AC/TZ cases was 27.2% preoperative, 66.0% pre-AC and 86.6%

Cardio Oncology 52

Cardio Oncology Cancer Heart Failure Risk Factors 52

DAIC

APRIL 3, 2024

24 news here.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Frontiers in Cardiovascular Medicine

JUNE 6, 2024

Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established.

Tachycardia 40

Tachycardia Cancer Cardio Oncology Arrhythmia 40

Cardiology Update

JANUARY 2, 2024

As we step into 2024, the field of cardiology continues to offer exciting opportunities for knowledge exchange and networking at in-person conferences. Here is a preview of the upcoming cardiology conferences planned for 2024.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

Cardiology Update

DECEMBER 3, 2023

Chadi Alraies discusses highlights from the American Heart Association (AHA) Scientific Sessions 2023, which were held in Philadelphia, Pennsylvania (PA), on November 11-13, 2023. There were many important developments in presented in key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023.

Research 98

Research Cardio Oncology COVID-19 Heart Failure 98

Cardiology Update

APRIL 9, 2024

The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. Here is our curated list of the top sessions. EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI).

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

American College of Cardiology

JANUARY 13, 2025

7 in JACC: CardioOncology.

Cardio Oncology 40

Cardio Oncology Outcomes Article 40